- Linagliptin
-
Linagliptin Systematic (IUPAC) name 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione Clinical data AHFS/Drugs.com Consumer Drug Information MedlinePlus a611036 Licence data US FDA:link Pregnancy cat. B(US) Legal status ℞-only (US) Routes Oral Identifiers CAS number 668270-12-0 ATC code A10BH05 PubChem CID 10096344 UNII 3X29ZEJ4R2 KEGG D09566 Chemical data Formula C25H26N8O2 Mol. mass 472.54 g/mol (what is this?) (verify) Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.
Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes.[1] It is being marketed by Boehringer Ingelheim and Lilly.
Mechanism of action
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output. Thus, linagliptin stimulates the release of insulin in a glucose-dependent manner and decreases the levels of glucagon in the circulation.
Clinical trials
Results in 2010 from a Phase III clinical trial of linagliptin showed that the drug can effectively reduce blood sugar.[2]
References
- H. Spreitzer (September 1, 2008). "Neue Wirkstoffe - BI-1356" (in German). Österreichische Apothekerzeitung (18/2008): 918.
- Wang, Y, Serradell, N, Rosa, E, Castaner, R (2008). "BI-1356". Drugs of the Future 33 (6): 473–477. doi:10.1358/dof.2008.033.06.1215244.
- ^ "FDA Approves Type 2 Diabetes Drug from Boehringer Ingelheim and Lilly". 3 May 2011. http://www.genengnews.com/gen-news-highlights/fda-approves-type-2-diabetes-drug-from-boehringer-ingelheim-and-lilly/81245092/.
- ^ "Four Phase III Trials Confirm Benefits of BI’s Oral, Once-Daily Type 2 Diabetes Therapy". Genetic Engineering & Biotechnology News. 28 June 2010. http://www.genengnews.com/gen-news-highlights/four-phase-iii-trials-confirm-benefits-of-bi-s-oral-once-daily-type-2-diabetes-therapy/81243585/.
Oral anti-diabetic drugs and Insulin analogs (A10) Insulin K+ ATPMeglitinides/"glinides"GLP-1 analogsExenatide • Liraglutide • Taspoglutide† • Albiglutide† • LixisenatideAnalogs/other insulinsfast-acting (Insulin lispro • Insulin aspart • Insulin glulisine) • short-acting (Regular insulin) • long-acting (Insulin glargine • Insulin detemir • NPH insulin) • ultra-long-acting (Insulin degludec†) • inhalable Exubera‡Other Amylin analogSGLT2 inhibitorsCanagliflozin† • Dapagliflozin† • Remogliflozin§ • Sergliflozin§OtherBenfluorex‡ • Tolrestat‡This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.